Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
about
Targeted immunotherapy for pediatric solid tumorsOsteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate TherapiesImmunotherapy of Childhood SarcomasOsteosarcoma: Current Treatment and a Collaborative Pathway to SuccessAdoptive cell therapy for sarcomaGanglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma.Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive SarcomaStructural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody.Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Future directions in the treatment of osteosarcoma.Advances in therapy for pediatric sarcomas.Immune-based therapies for childhood cancer.Advances in emerging drugs for osteosarcoma.Triptolide inhibits the growth of osteosarcoma by regulating microRNA-181a via targeting PTEN gene in vivo and vitro.Metastatic osteosarcoma: a challenging multidisciplinary treatment.Novel insights and therapeutic interventions for pediatric osteosarcoma.Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.Progress and opportunities for immune therapeutics in osteosarcoma.Drugs in early clinical development for the treatment of osteosarcoma.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma.Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.Current and future therapeutic approaches for osteosarcoma.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
P2860
Q26747703-FA46849E-D62D-4DBE-93BC-7AC922B87C1CQ26782646-BEE04525-6D6C-45E8-8C97-0BA8502BBC0AQ26795369-B2F4C097-704C-4E15-B60B-B895B2C9D943Q26797555-BC1622D8-FCD2-448D-B181-6EAE1E30A2BEQ27009541-B47A4C0C-604F-452E-A2B4-8A749806E55AQ35030373-F5552D79-DEEB-4371-963D-1EED504F7670Q35146479-91BBDF28-52E3-478E-BDCC-650B8A3FB1A5Q35598804-F4F8DF2E-5A9E-432C-A023-AD97D5E42A40Q36133953-02C84F47-617C-4AD0-8EE7-F5B73A21A625Q36157472-0A4486B4-70CF-4AC7-9E20-C15DE5E50499Q36261159-6CB193A2-1EA2-4561-AC4D-0856596C5537Q36600800-D239257B-B14F-40FB-85E7-B7837BD39650Q38217354-63DCF8C3-88E3-41CC-A59C-989492B46168Q38263108-1196A327-D23D-4D2A-BEF3-C26F374A22ABQ38506118-DAFA78EB-F29A-472F-A69F-A2B9B1DE99EAQ38708792-D00B88AB-069E-4EC3-9BD6-B46E2AB8E9B4Q38783252-03026238-014B-4CBC-8EDC-31BC56B553C3Q38819276-43AEA565-AF29-426A-B08F-03989B860D94Q38840985-3010C910-11BB-4497-BF87-2AD3E1C30FE6Q38948905-ED025249-76DE-47CB-AD10-09A7A4855C64Q38955517-F246B0D2-D0F4-46CC-BBFD-31BCF986958BQ39229404-D1DA2DCF-11B2-418F-9619-D94A404D1880Q39401628-4914194A-D987-4375-A447-E46CD6930BAEQ40137306-6E51AE74-EFD4-40CF-B131-0E6504DC65BFQ40700335-EED7A263-BFAB-4F07-A054-EFC30259D317Q41636566-D8CBCA27-F196-449D-A118-02FA12C2B589Q42576424-26725FAC-D4B2-4F7D-A9E3-91C36AB7CE4AQ47118215-9C0EA893-5763-4CC4-87B5-B11C54104522Q47360357-455448DD-B72F-4A4D-AF09-35DD627B1787Q47832898-4BE2A2BC-CDD7-4688-A5DF-D5D5CFA004EBQ49210694-C285E9C2-741E-4DF8-A46D-84C41F7C1333Q51039603-3EFD2F86-0A54-4CF2-B6CE-30545EC337ACQ51779979-8D727F3E-1A76-47B2-8CA6-9BF0C1359873
P2860
Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.
@en
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.
@nl
type
label
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.
@en
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.
@nl
prefLabel
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.
@en
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma.
@nl
P2093
P2860
P356
P1433
P1476
Ganglioside GD2 as a therapeut ...... in patients with osteosarcoma
@en
P2093
David Geller
John Tarim
Jonathan Gill
Marissa Linkowski
Michael Roth
Rebecca Sowers
Sajida Piperdi
P2860
P304
P356
10.1002/CNCR.28461
P407
P577
2013-10-25T00:00:00Z